Progression Of Antibody Defects
Gordon E. Myers, MD, Kenneth Paris, MD MPH, and Luke A. Wall, MD; LSU Health Sciences Center, Children's Hospital of New Orleans, New Orleans, LA. RATIONALE: While it is a commonly held idea that antibody deficiencies may worsen over time, there are very few published case examples. This report describes 7 pediatric patients with progression of an antibody deficiency over time. Such cases are important for building the knowledge needed to predict which children with recurrent infections might go on to develop a well-defined antibody deficiency. METHODS: We identified patients in our immunology clinic with recurrent sinopulmonary infections who were known to have a normal IgG level at initial evaluation, and went on to demonstrate new onset of an antibody defect or progression of an initially subtle defect. We performed a retrospective chart review documenting immunoglobulin levels, vaccine response, and memory B cells. Patients with malignancy or serum protein loss were excluded. RESULTS: Seven patients met criteria. At initial presentation, all had normal serum total IgG, two had absent IgA, and all had normal or elevated IgM. Over time, 6 of the 7 patients developed low IgG, 2 had a progressive loss of IgA, and 4 developed low IgM. Two patients failed to respond to both protein and polysaccharide vaccines. Five of these patients had abnormally low class-switched memory B cells. CONCLUSIONS: This study demonstrates the need for continued monitoring and periodic lab evaluation in children with a persistent pattern of sinopulmonary infections despite initially normal results. Susceptibility to infections may present early, when the antibody compartment appears intact. While additional studies are needed, low class-switched memory B cells could correlate with progression of antibody deficiencies. New York Medical College, Valhalla, NY. RATIONALE: IgG replacement is the primary treatment for patients with primary immunodeficiency (PI), however it is not commonly used in patients with lesser forms of disease, e.g. SAD, particularly the mild phenotype. We investigated the frequency of bronchiectasis in patients with PI including SAD. METHODS: Forty-seven patients with primary immune deficiencies underwent chest CT. All patients with bronchiectasis underwent grading with both the FACED Score and Bronchiectasis Severity Index (BSI) tools. RESULTS: Assessments for the BSI and FACED scores were similar. Of the 47 patients, 15/22 (68%) patients with SAD, mild phenotype had bronchiectasis; 7/14 (50%) patients had SAD, moderate phenotype and bronchiectasis; 1/1 (100%) of patients with SAD, severe phenotype had bronchiectasis; 4/5 (80%) with CVID had bronchiectasis; 15/41 (37%) of patients had no evidence of bronchiectasis; 5 patients refused CT scans (11%). Of the 42 patients with PI screened, 27 had some degree of bronchiectasis (64%). Twenty-five patients had mild bronchiectasis (62%); 2 patients had moderate bronchiectasis (5%). Of the 15 patients with SAD, mild phenotype and bronchiectasis, 100% had mild bronchiectasis; 6/ 7 patients with SAD, moderate phenotype had mild bronchiectasis (86%); 1 patient had moderate bronchiectasis (17%). The 1 patient with SAD, severe phenotype also had moderate bronchiectasis (100%). CONCLUSIONS: The incidence of bronchiectasis in patients with SAD, especially mild phenotype, is higher than previously thought. Consideration should be given to performing chest CT scans in all patients with SAD. If bronchiectasis is found, consideration should be made for IgG replacement. RATIONALE: MPS are lysosomal disorders caused by the deficiency of different enzymes that degrade glycosaminoglycans (GAG). Lysosome represents a vital component of the immune system through autophagy and antigen processing/presentation. Organ dysfunction modifies the immune response of these patients which, associated with structural factors, could lead to recurrent sinopulmonary infections. The aim of this study is to carry out the initial immunological evaluation of MPS patients. METHODS: Interviews were conducted across previous infections and laboratory tests for blood counts, serum immunoglobulins, and response to protein/polysaccharide vaccine of fourteen patients with MPS who were older than 4y/o and had complete vaccination schedule, including pneumococcal polysaccharide vaccine. RESULTS: All patients underwent enzyme replacement therapy (ERT). They have reported previous pneumonia and had improvement in the frequency of infections after ERT. Eleven patients (80%) had background of hospitalization due to low airway infections. Blood count and vaccine response to rubella were normal in all of them. However, 8 (57%) had no polysaccharide vaccine response. Over 70% had no response to pneumococcal serotypes 1 and 9. CONCLUSIONS: Infections are a major cause of death in MPS patients. Specific antibody response is a primary immunodeficiency and it may be evolved in the mechanisms leading to recurrent infections in these patients. Further studies are required to fully understand the reason why absence of specific antibody response is highly prevalent in this group.
